Idorsia Ltd
IDIA.SW
Swiss Exchange6.57
CHF
-0.06
- -
Idorsia Ltd
IDIA.SW
(Swiss Exchange)
Recent
price
6.57
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Idorsia Ltd is a biopharmaceutical company focused on the discovery, development and commercialization of innovative small-molecule drugs targeting unmet medical needs in central nervous system disorders, cardiovascular and immunological conditions, and rare diseases. The company offers QUVIVIQ (daridorexant), a dual orexin receptor antagonist commercially available in the US for treatment of insomnia characterized by difficulties with sleep onset and/or maintenance, and in Europe (Germany, Italy, Switzerland, Spain, UK, Austria, France, Sweden, Finland) and Canada with EU-wide approval; TRYVIO (aprocitentan) in the US and JERAYGO (aprocitentan) in the EU and UK, both dual endothelin receptor antagonists for resistant hypertension in combination with other antihypertensives; and advances a pipeline including lucerastat, a glucosylceramide synthase inhibitor for Fabry disease in Phase 3 open-label extension; daridorexant for pediatric insomnia in Phase 2; IDOR-1117-2520, a CCR6 antagonist for psoriasis entering proof-of-concept; ACT-777991, a CXCR3 antagonist for vitiligo; ACT-1004-1239, an ACKR3 antagonist for progressive multiple sclerosis; and early-stage chemokine antagonists, orexin agonists, LPA1 antagonists, synthetic glycan vaccines for Clostridium difficile and Klebsiella pneumonia infections, among others. Idorsia conducts operations primarily from Switzerland with commercial presence in the US, Europe and Canada, partnerships extending to Asia-Pacific via Nxera Pharma and Greater China via Simcere, and global development collaborations. Founded in 2017 following its demerger from Actelion after the latter's acquisition by Johnson & Johnson, Idorsia is headquartered in Allschwil, Switzerland, near Basel. Recent developments include a March 2024 global R&D collaboration with Viatris for Phase 3 assets selatogrel (P2Y12 inhibitor for acute myocardial infarction) and cenerimod (S1P1 modulator for systemic lupus erythematosus), with upfront payment of USD 350 million to Idorsia and amended terms in February 2025 reducing Idorsia's development contribution by USD 100 million while retaining royalties; FDA approval of TRYVIO and EU approval of JERAYGO in 2024 with commercial launches; September 2023 reacquisition of aprocitentan rights from Janssen Biotech; 2023 sale of Asia-Pacific (ex-China) operations to Nxera Pharma for CHF 400 million; December 2024 royalty monetization for vamorolone yielding USD 30 million; Simcere's launch of QUVIVIQ in China in September 2025 opening a royalty stream; February 2025 restructuring of convertible bond debt with new CHF 150 million funding facility; and workforce reductions to around 550 employees by early 2025 to streamline costs.
New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
Santhera schlägt Dr. Srishti Gupta als neues Mitglied des Verwaltungsrats
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
Idorsia's treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product' category